A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Recruiting now · Phase 2/Phase 3

Conditions studied: Metastatic Uveal Melanoma

In brief

The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been treated with immune checkpoint inhibitor therapy.

Key facts

Study ID

NCT06581406

Run by

Replimune, Inc.

People needed

280

Starts

2024-12-17

Expected to finish

2031-10-01

Last updated by the study team

2026-04-02

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

Where it is running

• HonorHealth Research Insisute — Scottsdale, Arizona, United States (enrolling)
• UC San Diego Moores Cancer Center — La Jolla, California, United States (enrolling)
• The Angeles Clinic and Research Institute — Los Angeles, California, United States (enrolling)
• University of California Los Angeles — Los Angeles, California, United States (enrolling)
• Stanford Cancer Institute — Palo Alto, California, United States (enrolling)
• University of Colorado Hospital - Anschutz Cancer Pavilion(ACP) — Aurora, Colorado, United States (enrolling)
• The Melanoma & Skin Cancer Institute — Englewood, Colorado, United States (enrolling)
• Georgetown University Medical Center — Washington D.C., District of Columbia, United States (enrolling)
• Mayo Clinic - Jacksonville FL — Jacksonville, Florida, United States (enrolling)
• Sylvester Comprehensive Cancer Center — Miami, Florida, United States (enrolling)
• Emory Winship Cancer Institute — Atlanta, Georgia, United States (enrolling)
• Northwestern Memorial Hospital — Chicago, Illinois, United States (enrolling)
• University of Chicago Medical Center — Chicago, Illinois, United States (enrolling)
• University of Iowa — Iowa City, Iowa, United States (enrolling)
• Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)
• Mayo Clinic Rochester — Rochester, Minnesota, United States (enrolling)
• Memorial Sloan Kettering Cancer Center — New York, New York, United States (enrolling)
• Duke University Medical Center — Durham, North Carolina, United States (enrolling)
• The Ohio State University — Columbus, Ohio, United States (enrolling)
• Thomas Jefferson University — Philadelphia, Pennsylvania, United States (enrolling)
• UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania, United States (enrolling)
• The West Clinic, PLLC dba West Cancer Center — Germantown, Tennessee, United States (enrolling)
• University of Tennessee Medical Center — Knoxville, Tennessee, United States (enrolling)
• Sarah Cannon Research Institute — Nashville, Tennessee, United States (enrolling)
• Vanderbilt Ingram Cancer Center (Henry-Joyce Cancer Clinic) — Nashville, Tennessee, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.